Novo Nordisk gets BACH1, inking IMMvention deal to orchestrate attack on sickle cell disease

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other chronic conditions.